Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity.
about
Molecular and therapeutic potential and toxicity of valproic acidTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderTargeting New Candidate Genes by Small Molecules Approaching Neurodegenerative DiseasesEpigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalitiesThe Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune DiseaseActivated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3βEffects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cellsAge-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiencyEffects of neonatal treatment with valproic acid on vasopressin immunoreactivity and olfactory behaviour in mice.Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury.Inflammation in ALS and SMA: sorting out the good from the evil.Pharmacology of epigenetics in brain disordersHDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammationHDAC6 regulates LPS-tolerance in astrocytes.Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactionsToll-like signaling and the cytokine IL-6 regulate histone deacetylase dependent neuronal survivalAcetylation preserves retinal ganglion cell structure and function in a chronic model of ocular hypertension.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancerThe therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosisColonic butyrate- algesic or analgesic?Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseNeonatal isoflurane exposure induces neurocognitive impairment and abnormal hippocampal histone acetylation in miceImaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.Intestinal Microbiota in Patients with Spinal Cord Injury.Antrodia camphorata Potentiates Neuroprotection against Cerebral Ischemia in Rats via Downregulation of iNOS/HO-1/Bax and Activated Caspase-3 and Inhibition of Hydroxyl Radical Formation.The neuroprotective effect of treatment of valproic Acid in acute spinal cord injury.Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell linesPersistent behavioral effects following early life exposure to retinoic acid or valproic acid in zebrafish.Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.Animal models of autism: an epigenetic and environmental viewpoint.HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in ratsValproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3Epigenetics and the modulation of neuroinflammation.Acetyltransferases (HATs) as targets for neurological therapeuticsEpigenetic control of sexual differentiation of the bed nucleus of the stria terminalis.Multiple roles of HDAC inhibition in neurodegenerative conditions.Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells.The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application.Drugs interfering with mitochondrial disorders.
P2860
Q21296867-92765539-7B56-481A-8907-C9C885325523Q24626017-37630F09-DBB5-4871-9CC2-6069144E2687Q26771812-B8830E1F-1981-4C8A-9801-28E7C87E95D9Q27023811-2BAC24B4-8733-477A-A90A-CF1AE92D5743Q28276657-12159848-4DC1-467F-94AC-6AFEB43C5817Q28383951-A414762F-A203-4947-8C70-DA9D12F4E993Q28571669-631E2458-D483-44E9-A122-DB80AA44C88BQ30052479-53E10420-3580-4B84-A27C-94039E70FA25Q30424752-8398CAB3-358E-46B0-BE7D-0D3E2F275F40Q30524207-01E0A007-4273-45A0-BA1B-C64909487062Q33664711-A6E660C3-3290-451B-AD92-D4E6ECEA331FQ33673025-625BF2E8-95A9-4FAB-A12F-CEF02C278672Q33757971-ED1119FE-7AD1-4544-9ED0-EC41F89C1088Q34055727-D7648AB6-3845-4044-9E88-C611690A9EE7Q34144718-DDBDB818-33B8-445C-B48E-145E2EC94B0EQ34358166-9E7422F6-BC95-416A-B2B4-BB9579585B57Q34557844-7B3DA8C8-E98F-4D31-85A7-497585E875C7Q35016934-1A0FA011-120A-486F-AD9F-E0CF905D1B73Q35016997-BFFB3B1D-84AD-4B00-9F42-BD65152EC198Q35328232-0A35121B-1692-4720-AF4B-2453692493F9Q35385117-306F912F-3C0D-4402-8126-6E4212070F45Q35558250-662141ED-0D0E-479A-B067-89663BE6C782Q35742545-262D48FC-11E9-4F58-BB7E-1286ACDEF656Q35890535-2E7A0C94-D0A8-4F5C-8DF4-F2D5B68D56EFQ36033846-8CEDBA83-748D-40F9-9E1B-4B4DBB97A75AQ36041142-4D674AB7-B7E0-45A2-8EE8-EBA6DDB35E89Q36368424-075D0209-4FAE-4FCA-B02D-DD92ACC2E940Q36578721-E4156E7F-A955-4194-99ED-F91CC507CF42Q36848206-E8291A53-281E-4615-ADB6-F5D700298D73Q36866412-694F0C56-30B2-41F5-9513-C94AB96EA2EDQ37120410-33F3C059-A0BD-4D04-A878-48F267913CECQ37220495-E6F271A6-EE05-47B0-BFA7-66868D4E73AFQ37249157-D996DE8E-1C4C-4830-AB08-228C5703134DQ37249167-CA5A7E71-A806-4740-A22C-210BF9CFB78AQ37328800-38B88B49-C629-4227-9505-E47C1BA6D0CFQ37407855-B6F44E9F-014B-4088-BB6D-3C89D0295AA8Q37445508-3E0DDA0D-712C-4F9A-8132-646198F3DBB4Q37460436-8FB753E0-DD70-4649-8C4C-F7E089FF4265Q37526428-5D045398-CCC4-4E82-8137-7C4AA81B0211Q37617357-38AACD38-E6CE-408A-9D29-CD26CB8C0DAC
P2860
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 July 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@en
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@nl
type
label
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@en
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@nl
prefLabel
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@en
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@nl
P2093
P2860
P921
P1433
P1476
Valproic acid and other histon ...... ed dopaminergic neurotoxicity.
@en
P2093
C D Bortner
D-M Chuang
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2007.06.053
P407
P577
2007-07-28T00:00:00Z